ImmunityBio Q1 Loss Narrows, Revenue Rises

Published on 12/05/2025 at 12:04

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ImmunityBio, Inc.

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Amid Tariff Pause	07-08	MT
ImmunityBio Granted UK Approval for Bladder Cancer Treatment	07-08	MT
UK MHRA Approves ImmunityBio?s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ	07-08	CI
UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication	07-04	MT
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients	06-02	MT
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors	06-02	CI
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva	06-02	RE
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East	05-27	MT
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East	05-27	CI
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding	05-27	RE
Sector Update: Health Care Stocks Advance Premarket Monday	05-12	MT
Immunitybio Q1 Revenue USD 16.517 Million	05-12	RE
ImmunityBio Q1 Loss Narrows, Revenue Rises	05-12	MT
Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss	05-12	MT
Earnings Flash (IBRX) IMMUNITYBIO INC. Reports Q1 Revenue $16.5M, vs. FactSet Est of $16.0M	05-12	MT
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
ImmunityBio Slides Following FDA Refusal-to-File Letter	05-05	DJ
ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy	05-05	MT
ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application	05-05	CI
ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May 2, 2025	05-05	RE
ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application	05-05	DJ
ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response	04-28	MT
ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG	04-28	CI
ImmunityBio, Inc. - Analyst/Investor Day	07-16
ImmunityBio Completes FDA License Application Submissions	04-15	MT